Published in Theor Biol Med Model on February 29, 2016
Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. Int J Mol Sci (2017) 0.75
'To test or not to test', the arguments for and against thrombophilia testing in obstetrics. Obstet Med (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods (2008) 126.81
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
On the origin of cancer cells. Science (1956) 49.55
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Network biology: understanding the cell's functional organization. Nat Rev Genet (2004) 36.62
Network motifs: simple building blocks of complex networks. Science (2002) 35.80
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Lethality and centrality in protein networks. Nature (2001) 29.64
Immunity, inflammation, and cancer. Cell (2010) 28.27
Error and attack tolerance of complex networks Nature (2000) 27.90
The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63
Hierarchical organization of modularity in metabolic networks. Science (2002) 22.47
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Specificity and stability in topology of protein networks. Science (2002) 21.07
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
The human disease network. Proc Natl Acad Sci U S A (2007) 19.58
The ground state of embryonic stem cell self-renewal. Nature (2008) 19.44
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev (2001) 14.02
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Clonal evolution in cancer. Nature (2012) 11.07
The life history of 21 breast cancers. Cell (2012) 10.59
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Biological robustness. Nat Rev Genet (2004) 9.98
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43
Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol (2007) 7.34
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res (2011) 6.90
Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet (2005) 6.85
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
The advantages and disadvantages of being polyploid. Nat Rev Genet (2005) 6.52
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Mass-spectrometry-based draft of the human proteome. Nature (2014) 6.32
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene (2006) 5.38
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer (2008) 5.19
Subnetwork hierarchies of biochemical pathways. Bioinformatics (2003) 4.99
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28
Literature-curated protein interaction datasets. Nat Methods (2009) 4.21
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia (2010) 3.93
A proteome-scale map of the human interactome network. Cell (2014) 3.91
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Towards a theory of biological robustness. Mol Syst Biol (2007) 3.82
Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. Proc Natl Acad Sci U S A (2004) 3.60
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 3.35
Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr (2004) 3.11
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol (2014) 2.82
An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia (2000) 2.73
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol (2005) 2.34
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med (2009) 2.33
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 2.32
Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2009) 2.31
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol (2007) 2.29
Preferential attachment in the protein network evolution. Phys Rev Lett (2003) 2.23
Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci (2013) 2.22
Design and application of a cytokine-receptor-based interaction trap. Nat Cell Biol (2001) 2.17
The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 2.15
Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol (2000) 2.15
Cancer genome sequencing: a review. Hum Mol Genet (2009) 2.15
A multiscale model for avascular tumor growth. Biophys J (2005) 2.14
Wnt signal transduction pathways. Organogenesis (2008) 2.14
Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci (2007) 2.07
Nanotechnology for the biologist. J Leukoc Biol (2005) 2.03
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases. BMC Genomics (2016) 0.75